Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | BID | P55957 | 3/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.54 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.54 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.54 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.54 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 3/20 | 0.47 |
| ▸ | F3 | P13726 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9094733 | 1.00 | KDM4E (0.57) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL29184951 | 1.00 | KDM4E (0.57) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL2270577 | 0.98 | KDM4E (0.55) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL5498415 | 0.98 | KDM4E (0.58) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL9295028 | 0.94 | KDM4E (0.60) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL22653038 | 0.87 | KDM4E (0.64) | KDM4EMAPTCYP1A2ALOX15ALDH1A1 | |
| SCHEMBL5922587 | 0.86 | BID (0.46) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL14786046 | 0.86 | BID (0.46) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL31500502 | 0.86 | BID (0.46) | KDM4EMAPTCYP1A2BIDMCL1 | |
| SCHEMBL18598998 | 0.86 | BID (0.44) | KDM4EMAPTCYP1A2BIDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | KDM4E 2656/4885MAPT 3441/4885CYP1A2 763/4885 |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | KDM4E 2710/4885MAPT 3652/4885CYP1A2 743/4885 |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | KDM4E 2656/4885MAPT 3441/4885CYP1A2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.